<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04048850</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0478</org_study_id>
    <nct_id>NCT04048850</nct_id>
  </id_info>
  <brief_title>Zepatier in Patients With Substance Use</brief_title>
  <official_title>Cohort Study of Hepatitis C Virus Treatment With Zepatier (Elbasvir/Grazoprevir) in Genotype 1 or 4 HCV Treatment-Naïve or Peginterferon/Ribavirin-Experienced Patients With Substance Use in Urban, Multidisciplinary Specialty Clinics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to assess hepatitis C virus (HCV) treatment with Zepatier&#xD;
      (elbasvir/grazoprevir) in HCV monoinfected and human immunodeficiency virus (HIV)-HCV&#xD;
      co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV&#xD;
      genotype 1a, without baseline NS5A resistance, 1b, or 4 and substance use in urban,&#xD;
      multidisciplinary specialty clinics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previously, people who use substances and those without liver fibrosis or cirrhosis were&#xD;
      excluded from receiving direct-acting antiviral (DAA) treatment due to Illinois Medicaid&#xD;
      restrictions. These sobriety and staging restrictions were recently lifted. However, due to&#xD;
      these previous stringent requirements for sobriety, many patients were not able to be treated&#xD;
      for HCV. This created a data gap for real-world outcomes of HCV treatment in people who use&#xD;
      substances. This study presents a unique opportunity to provide patients with hepatitis C&#xD;
      treatment and obtain much needed data on the use of elbasvir/grazoprevir in patients with&#xD;
      substance use and other underrepresented comorbidities. Additionally, this study will&#xD;
      determine if our current standard of care for the treatment of HCV is effective for patients&#xD;
      with substance use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SVR - PP</measure>
    <time_frame>12 weeks after the end of therapy (SVR-12)</time_frame>
    <description>Proportion of patients in the per-protocol (PP) population with sustained virologic response (SVR). PP: excludes non-treatment related discontinuations and patients lost to follow-up before SVR-12 laboratory test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SVR - stratified</measure>
    <time_frame>12 weeks after the end of therapy (SVR-12)</time_frame>
    <description>PP SVR-12 stratified by pre-specified baseline characteristics:&#xD;
HCV monoinfection&#xD;
HIV-HCV co-infection&#xD;
Cirrhosis&#xD;
Positive baseline urine toxicology&#xD;
Men who have sex with men (MSM)&#xD;
Commercial sex work&#xD;
Diagnosed concomitant psychiatric disorder(s)&#xD;
Use of concomitant medication(s)&#xD;
Specific substance(s) used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-Drug interactions (DDIs)</measure>
    <time_frame>From enrollment to treatment completion or termination, which ever comes first, for up to 36 weeks</time_frame>
    <description>Interventions to prevent or remedy known or suspected DDIs between elbasvir/grazoprevir and concomitant prescription or over-the-counter medications, supplements, and substance of use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>During 12 weeks of treatment</time_frame>
    <description>Self-reported adherence to elbasvir/grazoprevir, reported as number of missed doses and % missed doses of total doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR - ITT</measure>
    <time_frame>12 weeks after the end of therapy (SVR-12)</time_frame>
    <description>Proportion of patients in the intention-to-treat (ITT) population with SVR-12. ITT: all patients who received at least one dose of Zepatier (elbasvir/grazoprevir)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hiv</condition>
  <condition>Coinfection, HIV</condition>
  <condition>Substance Use Disorders</condition>
  <arm_group>
    <arm_group_label>Patients living with HCV +/- HIV</arm_group_label>
    <description>HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV genotype 1a, without baseline NS5A resistance, 1b, or 4 and substance use treated with elbasvir/grazoprevir 50-100 mg fixed-dose-combination, 1 tablet by mouth daily, for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]</intervention_name>
    <description>Daily medication</description>
    <arm_group_label>Patients living with HCV +/- HIV</arm_group_label>
    <other_name>Zepatier</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The specific patient population to be studied is HCV monoinfected and HIV-HCV co-infected,&#xD;
        HCV treatment-naïve or peginterferon/ribavirin-experienced patients of the UI Health&#xD;
        Infectious Disease or Liver Clinic with HCV genotype 1a, without baseline NS5A resistance,&#xD;
        1b, or 4 and substance use treated with 12 weeks of elbasvir/grazoprevir therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (at least 18 years of age or older)&#xD;
&#xD;
          -  Chronic HCV (HCV antibody positive with detectable HCV-RNA)&#xD;
&#xD;
          -  HCV genotypes 1a, without the presence of baseline NS5A resistance (specifically,&#xD;
             polymorphisms at amino acid positions 28, 30, 31, or 93), 1b, or 4&#xD;
&#xD;
          -  HCV treatment-naïve or peginterferon/ribavirin-experienced&#xD;
&#xD;
          -  Managed by the UI Health Infectious Diseases Clinic or Liver Clinic&#xD;
&#xD;
          -  Recent or current substance use (per self-report or electronic medical record (EMR)&#xD;
             data within 90 days of the screening visit, with or without positive baseline urine&#xD;
             toxicology), inclusive of one or more of the following: Opiate substitution therapy;&#xD;
             Prescription medication misuse (including: opiates, sedatives, tranquilizers,&#xD;
             hypnotics, and psychostimulants); Illicit substances; Injection drug use; Alcohol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incarcerated&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Decompensated liver disease (Child-Pugh B or C)&#xD;
&#xD;
          -  Albumin below 3 g/dL&#xD;
&#xD;
          -  Platelet count below 75,000&#xD;
&#xD;
          -  Unwilling to commit to treatment and/or monitoring&#xD;
&#xD;
          -  Poor venous access inhibiting laboratory collection&#xD;
&#xD;
          -  Any condition considered by the investigators to be a contraindication to study&#xD;
             participation&#xD;
&#xD;
          -  Hepatitis B virus (HBV) surface antigen (HBsAg) positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Michienzi, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago College of Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://hospital.uillinois.edu/</url>
    <description>University of Illinois at Chicago Hospital and Health Sciences System</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Sarah Michienzi</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>HIV-HCV coinfection</keyword>
  <keyword>DAA</keyword>
  <keyword>Elbasvir/grazoprevir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Coinfection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Grazoprevir</mesh_term>
    <mesh_term>Elbasvir-grazoprevir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

